Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluvastatin + tacrolimus + mycophenolate mofetil
- Development stage
- Phase 4
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination of three medications used in transplant medicine and autoimmune conditions. Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase to prevent T and B lymphocyte proliferation. Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation. Fluvastatin is a statin that can affect the metabolism of both immunosuppressants. This combination requires careful monitoring due to drug interactions.
02
Targets
CN (Calcineurin)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)
Beyond the preview
Go deeper on fluvastatin + tacrolimus + mycophenolate mofetil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluvastatin + tacrolimus + mycophenolate mofetil.